Translational Immunology

The Translational Immunology area was created in 2023 to meet a growing need in immunology competences linked to the development of new ATMPs (Gene and Cell Therapies).

Advances in both gene and cell immunotherapies rely on better understanding human immune responses.

Current approaches leading to the development of these new products rely critically on boosting immunological effectiveness while minimizing adverse immune reactions, such as immunity against the therapeutic agent or hyperinflammatory reactions. These aspects need to be considered early during product development.

Employing immune-genetic tools and strategies to:

• Develop universal target cells for immune potency tests
• Generate human induced pluripotent stem cell (hiPSC)-derived immune cells with defined effector functions.

The Translational Immunology team works closely with the Gene Therapy, Cell Therapy and Advanced Cell Models R&D teams to collaboratively solve the most pressing challenges at the intersection of immunology and ATMP/cell model development. 

Current research efforts are targeted at advancing hiPSC-derived immune cell differentiation and characterization for application in 3D advanced cell models and immune cell manufacturing.  

The team will also develop novel projects that will expand the iBET portfolio. On a long run, this endeavor will diffuse immunological competence to the whole institute and extend its spectrum of activities, thereby increasing excellence, competitiveness, and our stakeholders’ confidence in the ATMP field.